Log In

Cancer nanomedicines: oversold or underappreciated?

Files

cancer.pdf (649.61 KB)

Publication date

2017

Authors

van der Meel, RoyISNI 0000000419514423
Lammers, TwanISNI 0000000057759211
Hennink, WimISNI 0000000390382745

Editors

Advisors

Supervisors

DOI

https://doi.org/10.1080/17425247.2017.1262346

Document Type

Editorial

Metadata

Show full item record

Collections

Utrecht University Repository
Open Access logo

License

taverne

Abstract

Since the approval of liposomal doxorubicin (Doxil) and daunorubicin (DaunoXome) 20 years ago for the treatment of (HIV-related) Kaposi’s sarcoma, significant investment and research efforts have been geared toward the development of nanomedicines for cancer treatment. The benefits of formulating cancer drugs in lipid- and polymer-based nanocarrier systems regarding drug solubility, circulation time, biodistribution, and toxicity while maintaining (or even enhancing) therapeutic efficacy, have led to the approval of about a dozen cancer nanomedicines, including antibody-drug conjugates (ADCs)

Keywords

Cancer nanomedicines, Clinical translation, Clinical trials, Combination treatment, Drug delivery, Drug targeting, EPR effect, Triggered release, Taverne, Pharmaceutical Science, SDG 3 - Good Health and Well-being

Citation

van der Meel, R, Lammers, T & Hennink, W E 2017, 'Cancer nanomedicines : oversold or underappreciated?', Expert Opinion on Drug Delivery, vol. 14, no. 1, pp. 1-5. https://doi.org/10.1080/17425247.2017.1262346

URI

https://dspace.library.uu.nl/handle/1874/348233